# Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)

> **NCT02929498** · PHASE1,PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 7 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** GSK2879552
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT02929498
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-07-31
- **Primary completion:** 2018-01-31
- **Final completion:** 2018-01-31
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The risk benefit in the study population does not favor continuation of the study
- **Last updated:** 2019-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02929498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02929498, "Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02929498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*